Susquehanna Fundamental Investments LLC Makes New Investment in Insmed Incorporated (NASDAQ:INSM)

Susquehanna Fundamental Investments LLC bought a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 270,960 shares of the biopharmaceutical company's stock, valued at approximately $18,707,000. Susquehanna Fundamental Investments LLC owned approximately 0.15% of Insmed as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Sanctuary Advisors LLC acquired a new stake in Insmed in the third quarter valued at $248,000. Tidal Investments LLC increased its holdings in Insmed by 447.0% in the third quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company's stock valued at $1,759,000 after buying an additional 19,696 shares during the last quarter. Principal Financial Group Inc. raised its stake in Insmed by 12.9% during the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock valued at $136,648,000 after buying an additional 214,130 shares in the last quarter. Everence Capital Management Inc. acquired a new stake in Insmed during the fourth quarter valued at approximately $352,000. Finally, Harbor Capital Advisors Inc. lifted its holdings in Insmed by 237.1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company's stock worth $4,115,000 after buying an additional 41,918 shares during the last quarter.

Wall Street Analysts Forecast Growth

INSM has been the subject of a number of research analyst reports. Guggenheim reiterated a "buy" rating and issued a $101.00 price target on shares of Insmed in a report on Tuesday, February 25th. Royal Bank of Canada reiterated an "outperform" rating and set a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. Bank of America raised their price target on shares of Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Morgan Stanley increased their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $94.00.

Insmed Price Performance

INSM traded up $1.54 on Tuesday, reaching $71.40. The company had a trading volume of 1,846,282 shares, compared to its average volume of 2,309,490. The company has a market capitalization of $12.98 billion, a P/E ratio of -12.77 and a beta of 1.07. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a fifty day moving average of $74.10 and a 200-day moving average of $73.54. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, equities research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Activity

In other Insmed news, CFO Sara Bonstein sold 13,302 shares of Insmed stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $80.00, for a total value of $1,064,160.00. Following the transaction, the chief financial officer now owns 142,204 shares in the company, valued at approximately $11,376,320. The trade was a 8.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO William Lewis sold 6,830 shares of the company's stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the completion of the transaction, the chief executive officer now directly owns 233,924 shares in the company, valued at $16,412,107.84. This represents a 2.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 471,797 shares of company stock worth $37,621,239 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.